25 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
Teva upgraded at J.P. Morgan on upcoming catalysts https://seekingalpha.com/news/4077679-teva-stock-upgraded-jp-morgan-catalysts?source=feed_tag_israel Mar 08, 2024 - Teva Pharmaceutical (TEVA) receives an upgrade from J.P. Morgan, on upcoming positive catalysts as the bank reviews its specialty pharma coverage. Read more here.
Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities https://seekingalpha.com/article/4673481-teva-alvotech-simlandi-approval-opens-new-generic-market-opportunities?source=feed_tag_israel Feb 26, 2024 - Teva's stock has risen 32% since December, outperforming the SPY, buoyed by FDA approval of Simlandi, a biosimilar to Humira. Learn more about TEVA stock here.
Teva and Jiangsu announce partnership for distribution of AUSTEDO in China https://seekingalpha.com/news/4071489-teva-and-jiangsu-announce-partnership-for-distribution-of-austedo-in-china?source=feed_tag_israel Feb 26, 2024 - Teva Pharmaceutical and Jiangsu Nhwa forge a strategic partnership to enhance patient access to AUSTEDO, a drug for neurodegenerative and movement...
Teva Pharmaceutical: I Need To See Top-Line Growth Return Before Starting A Position https://seekingalpha.com/article/4670634-teva-pharmaceutical-i-need-to-see-growth-before-starting-a-position?source=feed_tag_israel Feb 15, 2024 - Teva Pharmaceutical's weak financial performance, declining revenues, and industry uncertainties make it a risky investment. Read why I rate TEVA stock a hold.
Teva upgraded to Overweight at Piper Sandler on multiple expansion https://seekingalpha.com/news/4065532-teva-stock-upgraded-piper-sandler-valuation?source=feed_tag_israel Feb 12, 2024 - Piper Sandler upgraded Teva Pharmaceutical (TEVA) to Overweight and raised its price target to $19 from $12 per share citing valuation. Read more here.
TEVA Q4 Earnings and Revenues Surpass Estimates, Stock Up https://www.zacks.com/stock/news/2219707/teva-q4-earnings-and-revenues-surpass-estimates-stock-up?cid=CS-ZC-FT-analyst_blog|earnings_article-2219707 Feb 01, 2024 - TEVA reports better-than-expected fourth-quarter results, beating both earnings and sales estimates. The stock gains 3% in response.
Teva Pharmaceutical Industries (TEVA) Q4 2023 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2024/01/31/teva-pharmaceutical-industries-teva-q4-2023-earnin/?source=iedfolrf0000001 Jan 31, 2024 - TEVA earnings call for the period ending December 31, 2023.
Teva Pharmaceutical Industries (TEVA) Q4 2023 Earnings Call Transcript https://seekingalpha.com/article/4666377-teva-pharmaceutical-industries-teva-q4-2023-earnings-call-transcript?source=feed_tag_israel Jan 31, 2024 - Teva Pharmaceutical Industries Limited (NYSE:NYSE:TEVA) Q4 2023 Earnings Conference Call January 31, 2024 8:00 AM ETCompany ParticipantsRichard Francis -...
Teva hits 52-week high on outlook, API divestment https://seekingalpha.com/news/4060755-teva-stock-hits-52-week-high-outlook?source=feed_tag_israel Jan 31, 2024 - Teva Pharmaceutical (TEVA) reached a new 52-week high after beating Q4 2023 forecasts and announcing plans to divest its API business. Read more here.
Teva Pharmaceutical Industries Ltd. (TEVA) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates https://www.zacks.com/stock/news/2218858/teva-pharmaceutical-industries-ltd-teva-q4-earnings-taking-a-look-at-key-metrics-versus-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2218858 Jan 31, 2024 - Although the revenue and EPS for Teva Pharmaceutical Industries Ltd. (TEVA) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Pages: 123

Page 1>